Fibrocor Therapeutics has appointed Mark Steedman as its first president and chief executive officer. He will also serve as a member of the company’s board of directors.   Fibrocor is focused on developing disease modifying therapeutics in fibrosis. Using a first-in class tissue discovery platform, Fibrocor has partnered with Evotec and MI to develop treatments to novel molecular targets and pathways in fibrosis. Mr. Steedman is the co-founder of Interface Biologics where he most re...